The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma

Schwameis, Richard; Grimm, Christoph; Petru, Edgar; Natter, C; Staudigl, Christine; Lamm, Wolfgang; Koelbl, Heinz; Krainer, Michael; Brodowicz, Thomas; Reinthaller, Alexander; Polterauer, Stephan

doi:10.1371/journal.pone.0133838

Cited by 10 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar correlation between CRP and FIGO stage was also detected by Hefler et al in a group of patients with epithelial ovarian cancer (13). Interestingly, in uterine leiomyosarcoma, a rare tumour of smooth muscle origin, the serum CRP level was not significantly associated with the FIGO stage (30).…”

Section: Discussionsupporting

confidence: 78%

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Bodner‐Adler

Kimberger

Schneidinger

et al. 2016

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer in women worldwide, with peak incidence in the 40-to 45-year age group (1). Adenocarcinoma of the uterine cervix is a rare histological subtype, representing up to 20% of cervical carcinoma. International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade, tumour size, lymphovascular space invasion and lymph node metastasis are major prognostic factors reported in literature (1-3). Nevertheless, additional information guiding the patient's management would be helpful. There is much interest in prognostic factors to permit more accurate patient stratification, that will improve clinical decision-making and may contribute to more rational treatment options. Current guidelines for cervical cancer recommend the same treatment regardless of histological subtype, although lower survival rates were reported for the adenocarcinoma subtype (4). Therefore increasing efforts should focus on prognosticators in adenocarcinoma of the uterine cervix.C-Reactive protein (CRP) is widely used in clinical routine as the most important acute-phase serum protein for monitoring infection. CRP has also been shown to be elevated in patients with a variety of cancer types and an association with prognosis was found. Several studies have shown that patients with cancer have a higher level of circulating CRP than healthy controls prior to clinical diagnosis (5-8). In addition, an increase in serum CRP has been reported to be associated with poor prognosis in oesophageal, liver, colon and lung cancer (9-12). Elevated serum CRP levels have also been linked to impaired survival in patients with different gynaecological malignancies, including cervical, ovarian and endometrial cancer (13-15). However, only few studies reported on the prognostic role of CRP expression in cervical carcinoma (14, 16), with no data investigating exclusively the histological subtype adenocarcinoma of the uterine cervix.The aim of the present study was to evaluate whether the pre-treatment serum CRP level might be used as a prognostic parameter in patients with adenocarcinoma of the uterine cervix and to investigate a possible correlation between the serum CRP level and various clinicopathological parameters. 4691

show abstract

Section: Discussionsupporting

confidence: 78%

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Bodner‐Adler

Kimberger

Schneidinger

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It is interesting that fibrinogen plasma concentrations did not correlate with patients’ age, since there is evidence that other acute phase proteins are elevated in older patients. However, similar results were found in another recent study with ULMS patients 25 .…”

Section: Discussionsupporting

confidence: 91%

“…For ULMS valid prognostic biomarkers are sparse. Recently markers such as CRP, GGT and CA 125 have been investigated for assessing prognosis in women with ULMS 23 – 25 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma – a multicenter study

Bekos

Grimm

Brodowicz

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Fibrinogen has an important pathophysiological role in tumor cell progression and development of metastases in different types of cancer. The present study aimed to evaluate the role of pre-treatment fibrinogen plasma concentrations as a biomarker for tumor biology and prognosis in patients with uterine leiomyosarcoma (ULMS). Clinical data of patients with ULMS were assessed in this multi-center study Pre-therapeutic fibrinogen plasma concentrations were evaluated. We investigated the association between fibrinogen plasma levels and clinico-pathological parameters and performed univariate and multivariable survival analyses. In total, 70 women with ULMS were included into the analysis. Mean (SD) pre-treatment fibrinogen plasma levels were 480.2 (172.3) mg/dL. Patients with advanced tumor stage, increased tumor size and higher histological grading had higher fibrinogen levels (p = 0.02, p = 0.013, and p = 0.029, respectively). In ULMS patients with increased fibrinogen levels 5-year overall survival (OS) rates were 25.0% compared to 52.9% in ULMS patients with normal fibrinogen, respectively. Univariate survival analyses revealed that elevated fibrinogen plasma levels (p = 0.030), advanced tumor stage (p < 0.001) and undifferentiated histology (p = 0.003) showed association with unfavorable OS. In multivariable analysis, histological grade (p = 0.03) and tumor stage (0.02) were independently associated with survival. Elevated fibrinogen plasma levels were associated with aggressive tumor biology and poor prognosis in women with ULMS. Fibrinogen might be useful as a novel biomarker in ULMS.

show abstract

“…Plasma fibrinogen level is an established laboratory test that is utilized in daily clinical routine and is relatively cheap. Previously only few serum biomarkers were shown to have prognostic value in women with ULMS [23][24][25] . Therefore we think that the identification of fibrinogen as a potential novel marker is clinically and scientifically relevant.…”

Section: Discussionmentioning

confidence: 99%

“…For ULMS valid prognostic biomarkers are sparse. Recently markers such as CRP, GGT and CA 125 have been investigated for assessing prognosis in women with ULMS [23][24][25] .…”

mentioning

confidence: 99%

Prognostic Role of Plasma Fibrinogen in Patients With Uterine Leiomyosarcoma – A Multicenter Study

Bekos¹

2017

Preprint

View full text Add to dashboard Cite

Fibrinogen has an important pathophysiological role in tumor cell progression and development of metastases in different types of cancer. The present study aimed to evaluate the role of pre-treatment fibrinogen plasma concentrations as a biomarker for tumor biology and prognosis in patients with uterine leiomyosarcoma (ULMS). Clinical data of patients with ULMS were assessed in this multicenter study Pre-therapeutic fibrinogen plasma concentrations were evaluated. We investigated the association between fibrinogen plasma levels and clinico-pathological parameters and performed univariate and multivariable survival analyses. In total, 70 women with ULMS were included into the analysis. Mean (SD) pre-treatment fibrinogen plasma levels were 480.2 (172.3) mg/dL. Patients with advanced tumor stage, increased tumor size and higher histological grading had higher fibrinogen levels (p = 0.02, p = 0.013, and p = 0.029, respectively). In ULMS patients with increased fibrinogen levels 5-year overall survival (OS) rates were 25.0% compared to 52.9% in ULMS patients with normal fibrinogen, respectively. Univariate survival analyses revealed that elevated fibrinogen plasma levels (p = 0.030), advanced tumor stage (p < 0.001) and undifferentiated histology (p = 0.003) showed association with unfavorable OS. In multivariable analysis, histological grade (p = 0.03) and tumor stage (0.02) were independently associated with survival. Elevated fibrinogen plasma levels were associated with aggressive tumor biology and poor prognosis in women with ULMS. Fibrinogen might be useful as a novel biomarker in ULMS.

show abstract

The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma

Cited by 10 publications

References 24 publications

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma – a multicenter study

Prognostic Role of Plasma Fibrinogen in Patients With Uterine Leiomyosarcoma – A Multicenter Study

Contact Info

Product

Resources

About